Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geneva-based Merck Serono, a division of Merck KGaA, reinforced its decision to continue investing in the therapeutic area of fertility, despite its parent company’s decision to withdraw the voluntary cash tender offer for MediCult A/S from the Oslo Stock Exchange.
Subscribe to our email newsletter
The parent company took the decision as MediCult A/S – a leader in Assisted Reproductive Technologies – did not reach the required share threshold within the set timeframe – as quoted in ca.sys-con.com.
Merck Serono offers a portfolio of fertility drugs to infertile couples at every stage of the reproductive cycle – from follicular development to early pregnancy, and produces the recombinant versions of the hormones required in the treatment of infertility namely GONAL-f FbM, Luveris, Cetrotide, Ovitrelle, Crinone and Pergoveris.
Richard Douge, Executive Vice President Global Marketing at Merck Serono said: “Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments.”